Search research articles
Contact Us
Filters
Showing results (101-110 of 130) with videos related to
Page
of 13
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M Tolaney, Yves Boucher, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2014
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901
Vanessa B Sheppard, Leigh Anne Faul, George Luta, et al.
NPJ Breast Cancer
|
September 27, 2017
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design
Jennifer A Ligibel, William T Barry, Catherine Alfano, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
JAMA Dermatology
|
October 13, 2021
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
Kristina M Harris, Dawn E Smilek, Margie Byron, et al.
JAMA
|
January 10, 2012
Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587
Chaitanya R Acharya, David S Hsu, Carey K Anders, et al.
JAMA
|
April 5, 2008
Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer
Chaitanya R Acharya, David S Hsu, Carey K Anders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 130) with videos related to
Sort By:
Page
of 13
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M Tolaney, Yves Boucher, Dan G Duda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2014
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901
Vanessa B Sheppard, Leigh Anne Faul, George Luta, et al.
NPJ Breast Cancer
|
September 27, 2017
Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design
Jennifer A Ligibel, William T Barry, Catherine Alfano, et al.
Gynecologic Oncology
|
August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
Elizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
The Lancet. Oncology
|
September 15, 2014
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Joyce F Liu, William T Barry, Michael Birrer, et al.
JAMA Dermatology
|
October 13, 2021
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial
Kristina M Harris, Dawn E Smilek, Margie Byron, et al.
JAMA
|
January 10, 2012
Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587
Chaitanya R Acharya, David S Hsu, Carey K Anders, et al.
JAMA
|
April 5, 2008
Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer
Chaitanya R Acharya, David S Hsu, Carey K Anders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A Carey, Donald A Berry, Constance T Cirrincione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.
Page
of 13